Evaluating Phase III PSMAddition Results for Pluvicto in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer from Novartis

Scheduled for:Dec 30, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

A medical oncologist or nuclear medicine specialist with expertise in genitourinary cancers, specifically prostate cancer. Ideally, the expert is familiar with radioligand therapy (RLT), PSMA-targeting agents, and has experience running or analyzing Phase III clinical trials.

Interview Goal

This interview aims to analyze the results of the Phase III PSMAddition trial investigating Pluvicto™ (lutetium-177 vipivotide tetraxetan) plus hormone therapy in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The discussion will explore the significance of the radiographic progression-free survival (rPFS) benefit, implications for earlier treatment lines, radioligand therapy mechanisms, and Pluvicto’s evolving role in prostate cancer care.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.